NCT05233553

Brief Summary

Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2022

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

February 9, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 10, 2022

Completed
Last Updated

February 10, 2022

Status Verified

February 1, 2020

Enrollment Period

1.8 years

First QC Date

February 9, 2022

Last Update Submit

February 9, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of SSC-COVID in hospitalized COVID-patients of the first wave

    While Follow-up-session controlled clinical and laboratory parameters

    one and a half year

Study Arms (1)

post-COVID-patients

Other: control of liver enzymes

Interventions

follow-up with clinical and laboratory measurements

post-COVID-patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This is a study of adult patients who participated in the COVID-19 outpatient clinic at the University Hospital of Tübingen as part of the follow-up examinations after COVID-19 disease. In particular, the development of liver enzymes was analysed.

You may qualify if:

  • post-COVID19-patients with required hospitalization during the first wave of COVID-19-pandemic
  • patients controlled at the university ambulance for follow-up

You may not qualify if:

  • children and patients younger than 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Tuebingen

Tübingen, 72076, Germany

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2022

First Posted

February 10, 2022

Study Start

March 1, 2020

Primary Completion

December 31, 2021

Study Completion

January 31, 2022

Last Updated

February 10, 2022

Record last verified: 2020-02

Locations